Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells

Tadao Funato, Tomonori Ishii, Mariko Kambe, Kevin J. Scanlon, Takeshi Sasaki

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)

Abstract

Colon cancer is one of the carcinomas that is resistant to a variety of therapies. To develop a new therapy by regulating the activated K-ras gene in colon cancers, we prepared synthetic DNA encoding the ribozyme (catalytic RNA), and inserted it into an expression vector (LNCX) originated from a retrovirus. Transfection of the vector into SW620 human colon cancer cells brought about significant suppression of K-ras mRNA synthesis and inhibition of the cell growth. Studies in athymic mice, in which K-ras ribozyme- introduced SW620 cells were transplanted, also revealed a marked reduction of tumor growth in vivo. Furthermore, the ribozyme-introduced tumors became more sensitive to treatment with anti-cancer drugs such as cisplatin, adriamycin, 5-fluorouracil, vincristine, and etoposide. These data suggest that the possible efficacy of anti-K-ras ribozyme increases the chemosensitivity of human colon cancers as well as the inhibitory effect on the growth of human colon cancers.

Original languageEnglish
Pages (from-to)495-500
Number of pages6
JournalCancer Gene Therapy
Volume7
Issue number3
DOIs
Publication statusPublished - 2000

Keywords

  • Anti-K-ras ribozyme
  • Colon cancer
  • Electroporation
  • Retrovirus vector

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Fingerprint Dive into the research topics of 'Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells'. Together they form a unique fingerprint.

Cite this